American Well Forecast Slumps as Analysts Remain on Hold

Forward-Looking Analysis

Wall Street analysts project a challenging quarter for American Well, forecasting revenue of $49.88 million for 2026Q2, a significant decline from the previous quarter’s $54.88 million. The consensus revenue range spans from $48.00 million to $53.00 million. Regarding profitability, the company is expected to report a net loss, with earnings per share (EPS) estimated at -$0.86. This represents a deterioration compared to the prior quarter’s EPS of -$0.66, with an estimated range between -$1.00 and -$0.63. Analyst sentiment remains cautious, with a consensus "Hold" rating derived from seven recent ratings, including one buy, six holds, and zero sells. The average 12-month price target is set at $8.90, implying a downside of approximately 17.67% from current trading levels. Price targets vary widely, ranging from a low of $6.50 to a high of $16.00. Notably, Wells Fargo upgraded its outlook in July 2026, raising its price target to $16.00 with a Buy rating, citing improved metrics. Conversely, Stifel Nicolaus and Morgan Stanley maintained Hold ratings with targets of $6.50 and $6.50, respectively, reflecting uncertainty regarding revenue growth recovery and government contract stability. The overall analyst consensus suggests limited upside potential, with most institutions advising investors to maintain existing positions rather than initiate new ones.

American Well’s 2026Q1 performance reflected continued pressure on top-line growth despite some operational efficiencies. The company reported total revenue of $54.88 million, marking a contraction in sales volume compared to prior periods. Net income for the quarter stood at a loss of $10.30 million, indicating persistent challenges in achieving profitability. Earnings per share were recorded at -$0.66, an improvement from the previous year’s deeper losses but still below break-even thresholds. Gross profit totaled $27.96 million, suggesting that while revenue declined, the company maintained a relatively stable gross margin structure during the quarter. These figures highlight the ongoing struggle to balance cost management with revenue expansion in a competitive telehealth landscape.

Additional News

American Well continues to operate as a micro-cap entity with a market capitalization of approximately $109.03 million. The stock has been trading near the bottom of its 52-week range, currently below its 200-day simple moving average, reflecting investor skepticism. In July 2026, Wells Fargo analyst Stan Berenshteyn boosted his price target to $16.00, maintaining an Overweight rating, which stands as the most bullish recent analyst action. However, other major institutions like Truist Financial and Morgan Stanley have reiterated Hold ratings with lower price targets of $7.50 and $6.50, respectively. Weiss Ratings also maintained a Sell rating (D-) in mid-July. The company’s platform continues to offer a broad suite of telehealth services, including urgent care, behavioral health, chronic care management, and virtual primary care. Despite these service offerings, the company faces headwinds from cautious revenue outlooks and uncertainties surrounding government contracts, which have contributed to the prevailing "Hold" consensus among the seven covering analysts. No major M&A activities, new product launches, or CEO changes were reported in the provided data.

Summary & Outlook

American Well’s financial health remains fragile, characterized by declining revenues and persistent net losses. While gross profits provide some stability, the path to sustained profitability is unclear. The primary risk catalyst is the projected revenue drop to ~$49.9 million, driven by market competition and contract uncertainties. Although Wells Fargo’s bullish stance offers a rare positive signal, the overwhelming consensus is neutral-to-bearish, with most analysts citing unproven growth recovery. Consequently, the outlook is neutral with a bearish tilt, as investors await evidence of revenue stabilization before considering significant re-ratings. The stock faces significant downside risk relative to analyst targets, suggesting caution for new capital allocation.